Optimizing Ultomiris Prior Authorization for Orthopedics

The Intersection of Complex Biologics and Orthopedic Care

While Ultomiris (ravulizumab), a C5 complement inhibitor, is primarily indicated for rare conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), orthopedic practices may encounter patients requiring this high-cost biologic. This intersection often arises when managing patients with co-morbid systemic conditions that necessitate specialized drug therapies alongside orthopedic procedures, adding a layer of administrative complexity to an already PA-intensive specialty.

Critical Documentation for Ultomiris Prior Authorization

• Confirmed diagnosis (ICD-10 codes) of the specific condition requiring Ultomiris
• Clinical rationale and medical necessity linking the drug to the patient's condition
• Documentation of failed prior therapies or contraindications to alternatives, if applicable
• Patient weight or body surface area (BSA) for accurate dosing calculations
• Relevant laboratory results (e.g., C5 levels, specific disease markers)
• Comprehensive treatment plan, including expected duration of therapy

Payer Scrutiny and Guideline Adherence for Ultomiris

As a high-cost medication, Ultomiris prior authorization is subject to rigorous payer medical policies. While orthopedic clinical practice guidelines like those from AAOS or ACR primarily govern procedures and imaging, Ultomiris PA typically requires adherence to specific diagnostic criteria, treatment protocols, and step-therapy requirements outlined in the drug's FDA-approved indications and payer formularies. Orthopedic teams must be prepared to document the medical necessity according to these specialized guidelines, which often reference hematology or nephrology consensus statements.

Mitigating Common Ultomiris PA Denial Triggers

• Incomplete documentation of diagnostic criteria for the underlying condition
• Insufficient evidence of failed prior therapies or adherence to step therapy protocols
• Missing or outdated laboratory results supporting medical necessity
• Lack of clear correlation between the patient's symptoms and the requested therapy
• Failure to meet payer-specific criteria for initiation or continuation of therapy
• Incorrect site-of-service designation for infusion, if applicable

Klivira's Role in Streamlining Complex Orthopedic and Drug PAs

Klivira's platform is engineered to manage the multi-faceted PA landscape of orthopedics, including the complexities of high-cost biologics. Our system integrates EMR data through SMART on FHIR, automating the retrieval of critical documentation for both orthopedic procedures (e.g., conservative-care trial duration, imaging history) and specialized drug PAs like Ultomiris (e.g., diagnosis codes, lab results, prior medication history). This comprehensive data aggregation ensures all necessary information is readily available for submission.

Addressing Orthopedic Workflow Constraints for Biologic Approvals

Orthopedic practices face significant workflow constraints, including high PA volume per surgeon and pre-operative scheduling pressures. Klivira addresses these by orchestrating multi-step PA cascades (e.g., imaging → surgery → DME) and streamlining drug PA processes. By automating the evidence collection and submission for high-scrutiny drugs, Klivira reduces the administrative burden on PA coordinators, allowing them to focus on complex cases and ensure timely approvals, minimizing delays in patient care.